Targeting complement in therapy

Immunological Reviews

Volumn 180, Issue , 2001, Pages 177-189

  Kirschfink, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; CD11B ANTIGEN; CD18 ANTIGEN; CD59 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

COMPLEMENT ACTIVATION; GRAFT REJECTION; INFLAMMATION; INFLAMMATORY CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC ANIMAL; TUMOR CELL DESTRUCTION; VASCULAR ENDOTHELIUM; XENOTRANSPLANTATION;

ANAPHYLATOXINS; ANGIONEUROTIC EDEMA; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, NEOPLASM; COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; DOGS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GRAFT REJECTION; GUANIDINES; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MACACA FASCICULARIS; MICE; NEOPLASMS; PANCREATITIS; RABBITS; RATS; RECEPTORS, COMPLEMENT; RECEPTORS, COMPLEMENT 3B; REPERFUSION INJURY; SWINE; TISSUE DONORS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034997865     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.1800116.x     Document Type: Review

References (171)

1. 1. Müller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem 1988;57:321-347.
2. 2. Rother K, Till GO, Haensch GM. The complement system. 2nd rev ed. Berlin, Heidelberg, New York: Springer; 1998.
3. 3. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996;17:532-540.
4. 4. Hugli TE. Biochemistry and biology of anaphylatoxins. Complement 1986;3:111-127.
5. 5. Morgan BP, Harris CL. Complement regulatory proteins ed. San Diego: Academic Press; 1999.
6. 6. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 1998;113:173-182.
7. 7. Morgan BP. Complement, Clinical aspects and relevance to disease. London, New York: Harcourt Brace Jovanovich; 1990.
8. 8. Volanakis JE, Frank MM. The human complement system in health and disease. New York, Basel, Hong Kong; Marcel Dekker; 1998.
9. 9. Walport MJ, Lachmann PJ. Complement deficiencies and abnormalities of the complement system in systemic lupus erythematosus and related disorders. Curr Opin Rheumatol 1990;2:661-663.
10. 10. Linton SM, Morgan BP. Complement activation and inhibition in experimental models of arthritis. Mol Immunol 1999;36:905-914.
11. 11. Mukherjee P, Pasinetti GM. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J Neuroimmunol 2000;105:124-130.
12. 12. Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci 1998;157:68-74.
13. 13. Putzu GA, Figarella Branger D, Bouvier Labít C, Líprandi A, Bíanco N, Pellissier JF. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barré syndrome. J Neurol Sci 2000;174:16-21.
14. 14. Zilow G, Sturm JA, Rother U, Kirschfink M. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 1990;79:151-157.
15. 15. Mollnes TE, Fosse E. The complement system in trauma-related and ischemic tissue damage: a brief review. Shock 1994;2:301-310.
16. 16. Moore FD, Caine WT. Emerging immunologic basis of reperfusion injury. Transplant Rev 2000;14:158-167.
17. 17. Lucchesi BR, Kilgore KS. Complement inhibitors in myocardial ischemia/reperfusion injury. Immunopharmacology 1997;38:27-42.
18. 18. De Boer JP, et al. Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immun 1993;61:4293-4301.
19. 19. Hack CE, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989;86:20-26.
20. 20. Colman RW. The role of plasma proteases in septic shock. N Engl J Med 1989;320:1207-1209.
21. 21. Hazelzet JA, et al. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998;66:5350-5356.
22. 22. Acioli JM, Isobe M, Kawasaki S. Early complement system activation and neutrophil priming in acute pancreatitis: participation of trypsin. Surgery 1997;122:909-917.
23. 23. Janatova J, Cheung AK, Parker CJ. Biomedical polymers differ in their capacity to activate complement. Complement Inflamm 1991;8:61-69.
24. 24. Johnson RJ. Complement activation during extracorporeal therapy: biochemistry, cell biology and clinical relevance. Nephrol Dial Transplant 1994;9(Suppl 2):36-45.
25. 25. Chenoweth DE. Anaphylatoxin formation in extracorporeal circuits. Complement 1986;3:152-165. 26.
26. Gardinali M, Circardi M, Agostoni A, Hugli TE. Complement activation in extracorporeal circulation: physiological and pathological implications. Pathol Immunopathol Res 1986:5:352-370.
27. 27. Cheung AK, Parker CJ, Hohnholt M. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 1994;46:1680-1687.
28. 28. Kirschfink M, Kovacs B, Mottaghy K. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces. Circ Shock 1993;40:221-226.
29. 29. Mollnes TE. Biocompatibility: complement as mediator of tissue damage and as indicator of incompatibility. Exp Clin Immunogenet 1997;14:24-29.
30. 30. Cooper NR, Nemerow GR, Mayes JT. Methods to detect and quantitate complement activation. Springer Semin Immunopathol 1983;6:195-212.
31. 31. Kirschfink M. The clinical laboratory: Testing the complement system In: Rother K, Till GO, H̄ansch GM, eds. The complement system, Berlin, New York: Springer; 1998. p. 522-547.
32. 32. Asghar SS. Pharmacological manipulation of complement system. Pharmacol Rev 1984;36:223-244.
33. 33. Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology 1997;38:51-62.
34. 34. Liszewski M-K, Atkinson JP. Novel complement inhibitors. Exp Opin Invest Drugs 1998;7:323-332.
35. 35. Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev 1998;50:59-87.
36. 36. Asghar SS, Pasch MC. Therapeutic inhibition of the complement system. Y2K update. Front Biosci 2000;5:E63-E81.
37. 37. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 1979;76:5867-5871.
38. 38. Weisman HF, et al. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians 1990;103:64-72.
39. 39. Fearon DT. Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors. Clin Exp Immunol 1991;86(Suppl 1):43-46.
40. 40. Weisman HF, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-151.
41. 41. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994;34:17-40.
42. 42. Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, Moore FD Jr. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol 1992;149:1723-1728.
43. 43. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ. Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J Physiol 1993;264:G801-G809.
44. 44. Chavez-Cartaya RE, DeSola GP, Wright L, Jamieson NV, White DJ. Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. Transplantation 1995;59:1047-52.
45. 45. Lehmann TG, et al. Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation. Transplantation 1998;66:717-722.
46. 46. Lazar HL, Bao Y, Gaudiani J, Rivers S, Marsh H. Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Circulation 1999;100:1438-1442.
47. 47. Pruitt SK, Baldwin WM 3rd, Marsh HC Jr, Lin SS, Yeh CG, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991;52:868-873.
48. 48. Rabinovici R, et al. Role of complement in endotoxin/platelet-activating factor-induced lung injury. J Immunol 1992;149:1744-1750.
49. 49. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995;5:1888-1894.
50. 50. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994;152:5477-5484.
51. 51. Naka Y, Marsh HC, Scesney SM, Oz MC, Pinsky DJ. Complement activation as a cause for primary graft failure in an isogeneic rat model of hypothermic lung preservation and transplantation. Transplantation 1997;64:1248-1255.
52. 52. Pierre AF, et al. Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function. Transplantation 1998;66:723-732.
53. 53. Heller A, Kunz M, Samakas A, Haase M, Kirschfink M, Koch T. The complement regulators C1 inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits. Shock 2000;13:285-290.
54. 54. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat monoarticular arthritis. Clin Exp Immunol 1997;110:45-52.
55. 55. Dreja H, Annenkov A, Chernajovsky Y. Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis Rheum 2000;43:1698-1709.
56. 56. Zimmerman JL, Dellinger RP, Straube RC, Levin JL. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000;28:3149-3154.
57. 2 chimeric complement inhibitor. J Exp Med 1991;174:1451-1460.
58. 58. Scesney SM, et al. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. Eur J Immunol 1996;26:1729-1735.
59. 59. Gralinski MR, Wiater BC, Assenmacher AN, Lucchesi BR. Selective inhibition of the alternative complement pathway by sCR1 (desLHR-A) protects the rabbit isolated heart from human complement-mediated damage. Immunopharmacology 1996;34:79-88.
60. 60. Rittershaus CW, et al. Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J Biol Chem 1999;274:11237-11244.
61. 61. Huang J, et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999;285:595-599.
62. 62. Tosi M, Duponchel C, Bourgarel P, Colomb M, Meo T. Molecular cloning of human C1 inhibitor: sequence homologies with α1-antitrypsin and other members of the serpins superfamily. Gene 1986;42:265-272.
63. 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma. FEBS Lett 1979;97:111-115.
64. 64. Patston PA, Gettins P, Beechem J, Schapira M. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991;30:8876-8882.
65. 65. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990;87:3753-3757.
66. 66. Brower MS, Harpel PC. Proteolytic cleavage and inactivation of α2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982;257:9849-9854.
67. 67. Davis AE 3rd., C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6:595-628.
68. 68. Späth PJ, Wüthrich B. Inherited and acquired deficiencies of C1 esterase inhibitor in humans In: Rother K, Till GO, Haensch GM, eds. The complement system. Berlin, Heidelberg, New York: Springer; 1998. p. 353-410.
69. 69. Faymonville ME, et al. Biochemical investigations after burning injury: complement system, protease-antiprotease balance and acute-phase reactants. Burns Incl Therm Inj 1987;13:26-33.
70. 70. Kowal-Vern A, Walenga JM, Sharp-Pucci M, Hoppensteadt D, Gamelli RL. Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor. J Burn Care Rehabil 1997;18:99-103.
71. 71. Carvalho AC, DeMarinis S, Scott CF, Silver LD, Schmaier AH, Colman RW. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 1988;112:270-277.
72. 72. Nurnberger W, et al. Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann Hematol 1993;67:17-21.
73. 73. Berling R, Ohlsson K. Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis. J Gastroenterol 1996;31:702-709.
74. 74. Mikkonen R, Aronen HJ, Kivisaari L, Plilonen A, Syrjala M. Plasma levels of prekallikrein, α-2-macroglobulin and C1-esterase inhibitor in patients with urticarial reaction to contrast media. Acta Radiol 1997;38:466-473.
75. 75. Gerlach M, Fohre B, Keh D, Riess H, Falke KJ, Gerlach H. Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients. Int J Artif Organs 1997;20:29-36.
76. 76. Kirschfink M, Nürnberger W. C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol 1999;36:225-232.
77. 77. Caliezi C. Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000;52:91-112.
78. 78. Guerrero R, et al. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J Clin Invest 1993;91:2754-2760.
79. 79. Scherer RU, Giebler RM, Schmidt U, Paar D, Kox WJ. The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability. Semin Thromb Hemost 1996;22:357-66.
80. 80. Fischer MB, et al. Increased susceptibility to endotoxin shock in complement C3-and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol 1997;159:976-982.
81. 81. Jansen PM, et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998;160:475-484.
82. 82. Hack CE, et al. C1-esterase inhibitor substitution in sepsis. Lancet 1992;339:378.
83. 83. Walger P, Fronhoffs S, Steuer K, Vetter H. The effect of C1-esterase inhibitor in five patients with streptococcal toxic syndrome. Ann Haematol 1997;74 Suppl:A160.
84. 84. Goodman AJ, Bird NC, Johnson AG. Antiprotease capacity in acute pancreatitis. Br J Surg 1986;73:796-798.
85. 85. Yamaguchi H, Kimura T, Mimura K, Nawata H. Activation of proteases in cerulein-induced pancreatitis. Pancreas 1989;4:565-571.
86. 86. Ruud TE, Aasen AO, Stadaas JO, Aune S. Effects on peritoneal proteolysis and hemodynamics of prophylactic and therapeutic infusions of high doses of aprotinin in experimental acute pancreatitis. Scand J Gastroenterol 1986;21:1011-1017.
87. 87. Yamaguchi H, Weidenbach H, Luhrs H, Lerch MM, Dickneite G, Adler G. Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Gut 1997;40:531-535.
88. 88. Niederau C, Brinsa R, Niederau M, Luthen R, Strohmeyer G, Ferrell LD. Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int J Pancreatol 1995;17:189-196.
89. 89. Testoni PA, et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 1995;42:301-305.
90. 90. Radke A, et al. C1-inhibitor prevents capillary leakage after thermal trauma. Crit Care Med 2000;28:3224-3232.
91. 91. Jostkleigreve F, Brandt KA, Janssen AC. C1-esterase inhibitor (C1-INH) as adjuvant therapy for septic shock following severe thermal trauma. Ann Haematol 1997;74(Suppl):A159.
92. 92. Rosenstein M, Ettinghausen SE, Rosenberg SA, Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986;137:1735-1742.
93. 93. Thijs LG, et al. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol 1990;144:2419-2424.
94. 94. Nurnberger W, Holthausen S, Michelmann I, Jurgens H, Burdach S, Gobel U. Generation of the complement activation product C5a precedes interleukin-2-induced capillary leakage syndrome. J Immunother Emphasis Tumor Immunol 1996;19:45-49.
95. 95. Ogilvie AC, et al, A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2. Br J Cancer 1994;69:596-598.
96. 96. Nurnberger W, Heying R, Burdach S, Gobel U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Haematol 1997;75:95-101.
97. 97. Stieh J, Harding P, Scheewe J, Dütschke P, Kramer HH. Capillary leak syndrome after open heart surgery for congenital heart defects: therapy with C1-inhibitor. Blomed Progr 1996;9:13-16.
98. 98. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995;91:393-402.
99. 99. Horstick G, et al. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997;95:701-708.
100. 100. Bauernschmitt R, Bohrer H, Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998;24:635-638.
101. 101. Salvatierra A, et al. C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. Am J Respir Crit Care Med 1997;155:1147-1154.
102. 102. Graeter T, Demertzis S, Scherer M, Langer F, Eisele B, Schäfers HJ. Amelioration of ischemia/reperfusion injury with C1-esterase inhibitor in a sheep lung transplant model. Ann Haematol 1997;74(Suppl):A156.
103. 103. Lehmann TG, Heger M, Münch S, Kirschfink M, Klar E. Complement inhibition by C1-esterase inhibitor reduces microvascular disturbance after warm hepatic ischemia. Langenbecks Arch Chir Suppl 1 Forumbd 1999;629-633.
104. 104. Hentjes B, et al. C1 -esterase-inhibitor levels in patients with and without reperfusion injury following lung transplantation (LTx). Ann Haematol 1997;74(Suppl):A157.
105. 105. Struber M, Hagl C, Hirt SW, Cremer J, Harringer W, Haverich A. C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med 1999;25:1315-1318.
106. 106. Marx G, et al. Septic shock after liver transplantation for Caroli's disease: clinical improvement after treatment with C1-esterase inhibitor. Intensive Care Med 1999;25:1017-1020.
107. 107. Morikis D, Assa-Munt N, Sahu A, Lambris JD. Solution structure of compstatin, a potent complement inhibitor. Protein Sci 1998;7:619-627.
108. 108. Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol 2000;165:2491-2499.
109. 109. Nilsson B, et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998;92:1661-1667.
110. 110. Fiane AE, et al. Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor compstatin. Transplant Proc 1999;31:934-935.
111. 111. Soulika AM, et al. Inhibition of heparin/protamine complex-induced complement activation by compstatin in baboons. Clin Immunol 2000;6:212-221.
112. 112. Hsueh W, Sun X, Rioja LN, Gonzalez-Crussi F. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 1990;70:309-314.
113. 113. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion; role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-2267.
114. 114. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8568.
115. 115. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995;92:8955-8959.
116. 116. Wang H, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation 1999;68:1643-1651.
117. 117. Thomas TC, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33:1389-1401.
118. 118. Rollins SA, et al. A humanized anti-C5 scFv blocks platelet and leukocyte activation and exhibits prolonged pharmacokinetics and pharmacodynamics in human. Exp Clin Immunogent 1997;14:36A.
119. 119. Rollins SA, et al. Anti-C5 single chain antibody therapy blocks complement & leukocyte activation and reduces myocardial tissue damage in CBP patients. Mol Immunol 1998;35:397A.
120. 120. Biesecker G, Dihel L, Enney K, Bendele R. Derivation of RNA aptamer inhibitors of human C5. Mol Immunol 1998;35:371A.
121. 121. Ember JA, Jagels MA, Hugli TE. Characterization of complement anaphylatoxins and their biological responses. In: Volonakis JE, Frank MM, eds. The human complement system. New York: Marcel Dekker; 1998. p. 241-284.
122. 122. Stevens JH, et al. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986;77:1812-1816.
123. 123. Smedegard G, Cui LX, Hugli TE. Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol 1989;135:489-497.
124. 124. Schmid E, et al. Requirement for C5a in lung vascular injury following thermal trauma to rat skin. Shock 1997;8:119-124.
125. 125. Bless NM, et al. Roles for C-X-C chemokines and C5a in lung injury after hindlimb ischemia-reperfusion. Am J Physiol 1999;276:L57-L63.
126. 126. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995;268:H448-H457.
127. 127. Hopken U, et al. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol 1996;26:1103-1109.
128. 128. Mohr M, et al. Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur J Clin Invest 1998;28:227-234.
129. 129. Ames RS, Tornetta MA, Jones CS, Tsui P. Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent Fab display library. J Immunol 1994;152:4572-4581.
130. 130. Kola A, et al. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis. Immunotechnology 1996;2:115-126.
131. 131. Pellas TC, Wennogle LP. C5a receptor antagonists. Curr Pharm Des 1999;5:737-755.
132. 132. Pellas TC, et al. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo. J Immunol 1998;160:5616-5621.
133. 133. Short A, et al. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol 1999;126:551-554.
134. 134. Riley RD, et al. Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization. J Thorac Cardiovasc Surg 2000;120:350-358.
135. 135. Mizuno M, Nishikawa K, Okada N, Matsuo S, Ito K, Okada H. Inhibition of a membrane complement regulatory protein by a monoclonal antibody induces acute lethal shock in rats primed with lipopolysaccharide. J Immunol 1999;162:5477-5482.
136. 136. Inagi R, Miyata T, Maeda K, Sugiyama S, Miyama A, Nakashima I. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol Lett 1991;27:49-52.
137. 137. Cheung AK, Parker CJ, Janatova J, Brynda E. Modulation of complement activation on hemodialysis membranes by immobilized heparin. J Am Soc Nephrol 1992;2:1328-1337.
138. 138. Edens ER, Linhardt RJ, Weiler JM. Heparin is not just an anticoagulant anymore: six and one-half decades of studies on the ability of heparin to regulate complement activity. In: Cruse JN, Lewis RE Jr, eds. Complement today. Vol 1. Basel: Karger; 1993. p. 96-120.
139. 139. Kirschfink M, Kovacs B, Mottaghy K. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces. Circ Shock 1993;40:221-226.
140. 140. Redmond JM, et al. Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg 1993;56:474-478.
141. 141. Moen O, et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997;63:105-111.
142. 142. Schreurs HH, et al. Heparin-coated bypass circuits: effects on inflammatory response in pediatric cardiac operations. Ann Thorac Surg 1998;66:166-171.
143. 143. Thomas H, Maillet F, Letourneur D, Jozefonvicz J, Fischer E, Kazatchkine MD. Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. Mol Immunol 1996;33:643-648.
144. 144. Miletic VD, Hester CG, Frank MM. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996;156:749-757.
145. 145. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
146. 146. Platt JL, Bach FH. The barrier to xenotransplantation. Transplantation 1991;52:937-947.
147. 147. Kirschfink M, Haferkamp A, Pomer S, Chrupcala M, Wosnik A, Heckl-Ostreicher B. Significance of the complement system for xenotransplantation: strategies for therapeutic intervention. Zentralbl Chir 1998;123:793-797.
148. 148. Dalmasso AP. The complement system in xenotransplantation. Immunopharmacology 1992;24:149-160.
149. 149. Heckl-Ostreicher B, Wosnik A, Kirschfink M. Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection. Transplantation 1996;62:1693-1696.
150. 150. Kooyman DL, et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995;269:89-92.
151. 151. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995;1:964-966.
152. 152. Cozzi E, Masroor S, Soin B, Vial C, White DJ. Progress in xenotransplantation. Clin Nephrol 2000;53:13-18.
153. 153. Waterworth PD, et al. Life-supporting pig-to-baboon heart xenotransplantation. J Heart Lung Transplant 1998;17:1201-1207.
154. 154. Zaidi A, et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998;65:1584-1590.
155. 155. Chen RH, Naficy S, Logan JS, Diamond LE, Adams DH. Hearts from transgenic pigs constructed with CD59/DAF genomic clones demonstrate improved survival in primates. Xenotransplantation 1999;6:194-200.
156. 156. Cowan PJ, et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000;69:2504-2515.
157. 157. Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 1991;50:350-355.
158. 158. Chrupcalla M, Pomer S, Staehler G, Waldherr R, Kirchfink M. Prolongation of discordant renal xenograft survival by depletion of complement. Comparative effects of systematically administered cobra venom factor and soluble complement receptor type 1 in a guinea pig-to-rat modal. Transplant Int 1994;7:650-653.
159. 159. Rollins SA, Matis LA, Springhorn JP, Setter E, Wolff DW. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 1995;60:1284-1292.
160. 160. Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK, Yeh CG. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. J Immunol 1997;158:2872-2881.
161. 161. Kroshus TJ, Salerno CT, Yeh CG, Higgins PJ, Bolman RM 3rd, Dalmasso AP. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation. Transplantation 2000;69:2282-2289.
162. 162. Kroshus TJ, et al. Complement inhibition with an anti-CS monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1996;60:1194-1202.
163. 163. Ohanian SH, Schlager SI. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense. Crit Rev Immunol 1981;1:165-209.
164. 164. Jurianz K, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999;36:929-939.
165. 165. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999;11;558-562.
166. 166. Junnikkala S, Hakulinen J, Meri S. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of melanoma cells. Eur J Immunol 1994;24:611-615.
167. 167. Harris CL, Kan KS, Stevenson GT, Morgan BP. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin Exp Immunol 1997;107:364-371.
168. 168. Blok VT, et al. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998;160:3437-3443.
169. 169. Hakulinen J, Meri S. Complement-mediated killing of microtumors in vitro. Am J Pathol 1998;153:845-855.
170. 170. Wuerzner R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 1999;36:249-260.
171. 171. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol 2000;18:861-929.